Speciality Medicines has scheduled its fifth annual general meeting for September 28, 2026, with remote e-voting opening on September 25. The company’s board approved the draft directors’ report for FY26 on September 3.

The meeting will be conducted through video conferencing or other audio-visual means in compliance with Ministry of Corporate Affairs and SEBI circulars. The board meeting that concluded the approvals took place at the corporate office in Mumbai from 3:00 pm to 3:40 pm on September 3.

E-Voting Window

National Securities Depository Limited (NSDL) has been appointed as the remote e-voting agency. The voting timeline is structured as follows:

Members recorded in the register of beneficial owners as on the cut-off date of September 21, 2026, are entitled to vote. Since all equity shares are held in dematerialised form, the register of members and share transfer books will not be closed.

Director Reappointment

The agenda includes the reappointment of Mr. Sumit Babubhai Goyani (DIN 07885780), who retires by rotation. As Whole-Time Director, he seeks reappointment under Section 152 of the Companies Act, 2013.

Mr. Goyani holds a Bachelor of Engineering in Mechanical Engineering and has served as a director since February 5, 2021. He was appointed CEO & Managing Director in October 2021 and redesignated as Whole-Time Director in June 2024. He attended all 19 board meetings in FY25-26 and drew remuneration of ₹34.10 lakhs for the year. As of March 31, 2026, he held 1,815,250 shares.

Meeting Logistics

CS Hardikkumar Jetani has been appointed as the scrutinizer to ensure a fair voting process. Institutional shareholders must submit board resolutions authorizing their representatives to vote via email to the scrutinizer. The notice and annual report are available on the company website and exchange portals.

Speciality Medicines Limited has secured regulatory approval from the competent health authority in Ethiopia for two additional speciality pharmaceutical formulations. The approvals, announced on August 12, 2026, cover Olanzapine Tablets 5 mg (brand name Olazyn 5) and Diazepam Tablets 5 mg (brand name Diazem 5).

The new registrations strengthen the company's export footprint in the African region. With these additions, Speciality Medicines now holds 12 registered formulations in Ethiopia. Including its existing registrations in Peru, the company's total global registered product portfolio stands at 14 formulations.

Product Registration Details

The newly approved products fall under the central nervous system (CNS) therapeutic category. Both formulations carry a validity period of five years.

Strategic Significance

The approvals reflect continued progress in Speciality Medicines' international registration strategy across Africa and Latin America. The addition of Olazyn 5 and Diazem 5 expands the range of speciality products available to overseas partners within the CNS segment.

The company continues to pursue additional international filings, with formulations currently under regulatory review across multiple overseas markets as part of its broader export expansion strategy.

Management Commentary

Sumit Goyani, Whole-Time Director, stated that the approvals mark another step forward in strengthening the company's presence in Ethiopia and expanding its speciality portfolio across international markets. He noted that Ethiopia remains an important market, with these registrations strengthening the product range offered through overseas partners.

Goyani added that the regulatory and quality teams continue working on additional filings and approvals across target export geographies, aiming to deepen international presence and support long-term export growth.

About the Company

Incorporated in 2021, Speciality Medicines Ltd is a speciality pharmaceutical company engaged in the marketing, distribution, and international commercialization of high-value pharmaceutical formulations. The company focuses on key therapeutic areas including oncology, immunology, neurology, and rare diseases, offering a diversified portfolio of speciality medicines across multiple dosage forms.